Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 54-year-old woman with a history of diffuse large B-cell lymphoma presents to the emergency department with chills and a temperature of 38.9∘C38.9^\circ\text{C} (102.0∘F102.0^\circ\text{F}). She received her last cycle of cytotoxic chemotherapy 8 days ago. Laboratory studies show a white blood cell count of 700/mm3700/\text{mm}^3 with 30%30\% neutrophils (absolute neutrophil count: 210/mm3210/\text{mm}^3). She is hemodynamically stable, has a central venous port in place, and has no localizing signs of infection on physical examination. Arrange the following steps in the optimal sequence for the evaluation, monitoring, and therapeutic de-escalation of this patient's condition.

  1. 1Obtain two sets of blood cultures (peripheral and central venous port) and baseline diagnostic studies.
  2. 2Administer empiric broad-spectrum intravenous antibiotics (e.g., cefepime) within one hour.
  3. 3Monitor the absolute neutrophil count (ANC) daily and assess clinical response.
  4. 4Transition to an appropriate oral antibiotic regimen once the patient is afebrile for at least 48 hours and clinically stable.
  5. 5Discontinue all antimicrobial therapy when the ANC recovers to greater than 500/mm3500/\text{mm}^3.

Cevap

The optimal sequence for managing high-risk febrile neutropenia begins with obtaining cultures, immediately administering broad-spectrum intravenous antibiotics, monitoring the ANC daily, transitioning to oral therapy when clinically stable and afebrile, and finally discontinuing antibiotics upon marrow recovery.
The standard of care for febrile neutropenia (fever ≥38.3∘C\ge 38.3^\circ\text{C} or sustained ≥38.0∘C\ge 38.0^\circ\text{C} for 1 hour with an ANC <500/mm3< 500/\text{mm}^3) dictates an immediate, step-wise approach. First, appropriate diagnostic tests (including blood cultures from all lumens of central lines and peripheral sites) must be obtained. Second, due to the risk of rapid clinical decline, empiric broad-spectrum intravenous antibiotics with antipseudomonal activity (e.g., cefepime, meropenem, piperacillin-tazobactam) must be administered within 1 hour. Third, the patient requires daily monitoring of the ANC and clinical status. Fourth, once the patient has been afebrile for at least 48 hours and demonstrates clinical stability, the regimen can be de-escalated from intravenous to oral antibiotics. Finally, all antimicrobial therapy can be safely discontinued once the ANC demonstrates sustained recovery to >500/mm3>500/\text{mm}^3.

Adım Adım Çözüm

1
Identify the patient as having high-risk febrile neutropenia.
The patient has an absolute neutrophil count (ANC) < 500/mm³ and a fever, requiring immediate intervention.
Febrile neutropenia is an oncologic emergency with high mortality if left untreated.
2
Sequence the diagnostic workup first.
Blood cultures must be drawn prior to administering any antibiotics.
Antibiotics rapidly sterilize the blood, making pathogen identification impossible if administered beforehand.
3
Sequence the initial acute treatment next.
Administer empiric intravenous antibiotics within 60 minutes of presentation.
Delays in broad-spectrum antibiotic administration significantly increase mortality in neutropenic patients.
4
Sequence the ongoing evaluation and monitoring.
Monitor daily ANC and fever curves.
The clinical response to empiric therapy must be tracked to guide future de-escalation decisions.
5
Sequence the initial therapeutic de-escalation.
Transition to oral antibiotics once the patient is afebrile for 48 hours.
Intravenous access is no longer strictly necessary once the patient is hemodynamically stable and defervesces, which reduces hospital length of stay and line-associated risks.
6
Sequence the final cessation step.
Discontinue all antibiotics when the ANC exceeds 500/mm³.
Once the immune system recovers sufficiently to fight off opportunistic infections, antimicrobial treatment can be safely stopped.

Anahtar Kavram

Monitoring and Treatment Evaluation in Febrile Neutropenia
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru